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In vivo test
Recently, our group has proposed a combinatorial strategy in tissue engineering principles employing
carboxymethylchitosan/poly(amidoamine) dendrimer nanoparticles (CMCht/PAMAM) towards the intra-
cellular release and regimented supply of dexamethasone (Dex) aimed at controlling stem cell osteogenic
differentiation in the absence of typical osteogenic inducers, in vivo. In this work, we have investigated if the
Dex-loaded CMCht/PAMAM dendrimer nanoparticles could play a crucial role in the regulation of
osteogenesis, in vivo. Macroporous hydroxyapatite (HA) scaffolds were seeded with rat bone marrow
stromal cells (RBMSCs), whose cells were expanded in MEMmedium supplemented with 0.01 mg ml−1 Dex-
loaded CMCht/PAMAM dendrimer nanoparticles and implanted subcutaneously on the back of rats for 2 and
4 weeks. HA porous ceramics without RBMSCs and RBMSCs/HA scaffold constructs seeded with cells
expanded in the presence and absence of 10−8 M Dex were used as controls. The effect of initial cell number
seeded in the HA scaffolds on the bone-forming ability of the constructs was also investigated. Qualitative
and quantitative new bone formation was evaluated in a non-destructive manner using micro-computed
tomography analyses of the explants. Haematoxylin and Eosin stained implant sections were also used for
the histomorphometrical analysis. Toluidine blue staining was carried out to investigate the synthesis of
proteoglycan extracellular matrix. In addition, alkaline phosphatase and osteocalcin levels in the explants
were also quantiﬁed, since these markers denote osteogenic differentiation. At 4 weeks post-implantation
results have shown that the novel Dex-loaded carboxymethylchitosan/poly(amidoamine) dendrimer
nanoparticles may be beneﬁcial as an intracellular nanocarrier, supplying Dex in a regimented manner
and promoting superior ectopic de novo bone formation.
© 2010 Elsevier Inc. All rights reserved.
Introduction
A variety of hydroxyapatite (HA) ceramics with controlled
architectures [1–3] has been developed to ﬁnd applications as bone
substitutes in the clinic. Despite, their interesting architecture namely
pore size, shape and interconnectivity, mechanical properties and
important biological role in the in vivo performance, these porous
implants lack on its osteoinductive capacity [4–6]. In this regard, it has
been shown that porous HA ceramics alone, do not induce bone
formation in soft tissues when implanted in rabbits [7], or upon
subcutaneous implantation in mice [8,9], rats [10–12] and goats [13].
By its turn, bone marrow stromal cells (BMSCs) have shown to
inherently possess a huge therapeutic potential [14–20]. As a possible
alternative, a combination of bone marrow stromal cells (BMSCs)
with porous scaffolds [10,11,13,21] has been widely explored in bone
tissue engineering strategies. On the other hand, it has been shown
that glucocorticoids such as dexamethasone (Dex) have an essential
role for osteoblast differentiation and matrix mineralization [22–24].
In fact, it has been reported that Dex regulation depends on the degree
of cellular differentiation, the donor species, and dosage, dose
duration and dosing regimen [25]. Several authors [9,10,26] reported
that stem cells need to be under the inﬂuence of such type of
osteogenic factors for superior de novo bone formation. Actually, cell-
scaffold constructs showed in vivo bone formation within the pores of
the scaffolds when constructs were ﬁrstly in vitro cultured under
osteogenic factors [10,11]. However, the long culturing time is a major
drawback of this strategy and may not be the most feasible to
satisfactorily meet clinical demands. Bearing in mind these premises,
Bone 46 (2010) 1424–1435
⁎ Corresponding author. 3B's Research Group - Biomaterials, Biodegradables and
Biomimetics, Univ. Minho, Headquarters of the European Institute of Excellence on
Tissue Engineering and Regenerative Medicine, AvePark, S. Cláudio de Barco, 4806-909
Taipas, Guimarães, Portugal. Fax: +351 253510909.
E-mail address: rgreis@dep.uminho.pt (R.L. Reis).
8756-3282/$ – see front matter © 2010 Elsevier Inc. All rights reserved.
doi:10.1016/j.bone.2010.02.007
Contents lists available at ScienceDirect
Bone
j ourna l homepage: www.e lsev ie r.com/ locate /bone
we foresee that cells may not maintain in vivo the cellular phenotype
uponwithdrawal of Dex, since Dex acts at both early and late stages to
direct proliferative osteoprogenitor cells toward terminal maturation
[27]. In fact, Castano-Izquierdo et al. [28] demonstrated that an in vitro
pre-culture period of rat mesenchymal stem cells (rMSCs) in
osteogenic media inﬂuences their in vivo bone-forming potential
when implanted to an orthotopic site (rat critical cranial size defect).
This study revealed that an enhanced de novo bone formation
occurred when in vitro pre-culture of rMSCs lasted for 4 days, while
the lowest bone formation was obtained with rMSCs cultured for
16 days. Therefore, the role of Dex is a critical factor in bone tissue
regeneration and still remains an open issue [29] that needs further
research namely what concerns with the development of alternative
approaches to improve the limited cell-derived osteogenesis. In this
context, we have been hypothesizing that the ex vivo culturing of stem
cells with functional nanoparticles which can be efﬁciently taken up
by cells may inﬂuence their cellular fate in the absence of typical
osteogenic inducers, in vivo. It has been shown that glucocorticoids
such as Dex bind to and triggers the cytoplasmatic glucocorticoid
receptor [30,31]. Thus, we expect that the culturing of stem cells in the
presence of nanoparticles that release Dex from inside, and in a
regimented manner may be an effective strategy for in vivo control of
stem cell osteogenic differentiation and maturation. In this regard, we
have surface engineered low generation poly(amidoamine) dendri-
mers with carboxymethylchitosan, CMCht/PAMAM dendrimer nano-
particles and loaded them with Dex [32]. These are expected to
possess high drug loading ability and non-cytotoxic behaviour as
compared to amine-terminated poly(amidoamine) dendrimers of
high generation. The use of Dex-loaded CMCht/PAMAM dendrimer
nanoparticles can also allow to avoid the need and frequency of drug
administration as Dex which is available at the target site possibly
minimizes the undesired side effects [31].
In previous studies [32,33], we have shown the high efﬁciency of
Dex-loaded CMCht/PAMAM dendrimer nanoparticles on being
internalized by different cell types, in vitro. The Dex release proﬁle
from the CMCht/PAMAM nanoparticles was monitored, in the
presence and absence of serum proteins at physiological pH. This
study has shown that Dex is released as a free drug in the range of
concentrations similar to that of typical osteogenic cocktails.
Complementarily, we demonstrated their role in promoting the
osteogenic differentiation of rat bone marrow stromal cells (RBMSCs)
in tissue culture polystyrene, TCPS dishes.
Our group [34,35] has recently developed HA scaffolds with
macroporous structure and reported that they are non-cytotoxic and
efﬁciently support the adhesion, proliferation and osteogenic differ-
entiation of RBMSCs in the presence of 0.01 mg ml−1 Dex-loaded
CMCht/PAMAM dendrimer nanoparticles, in vitro. Thus, the HA
scaffolds have shown to possess promising physicochemical and
biological properties for use in bone tissue engineering approaches. To
further evaluate the in vivo performance of the cell-scaffold
constructs, several groups [10,11,26,36] have been proposing the
well established ectopic implantation model in rats. This is a cost
effective model [37] and allows to avoid the presence of growth
factors found at the orthotopic site whose inﬂuence may affect the
performance of the constructs [38].
In the current experimental study, we investigate if the Dex-
loaded CMCht/PAMAM dendrimer nanoparticles play a crucial role in
the regulation of osteogenesis, in vivo. We therefore used RBMSCs/HA
construct whose cells were exposed to 0.01 mg ml−1 Dex-loaded
CMCht/PAMAM dendrimer nanoparticles during the expansion time
(Fig. 1, top) and assess their efﬁciency in promoting the osteogenic
differentiation and de novo bone formation upon subcutaneous
implantation on the back of rats for the period of 2 and 4 weeks. HA
macroporous ceramics and RBMSCs/HA constructs seeded with
different cell numbers and cultured either in the presence or absence
of Dex were used as controls for elucidating the role of the Dex-loaded
CMCht/PAMAM dendrimer nanoparticles in promoting osteogenesis.
Micro-computed tomography (micro-CT) analyses were performed to
investigate new bone formation in the RBMSCs/HA constructs.
Histological studies were also carried out using Haematoxylin and
Eosin staining. Histomorphometrical analysis of the implant sections
and 3D micro-CT reconstructions were performed to quantify new
bone formation. Toluidine blue staining was also performed to
investigate the synthesis of proteoglycan extracellular matrix.
Complementarily, osteoblastic phenotype expression levels were
determined by quantiﬁcation of the surface-membrane alkaline
phosphatase (ALP) glycoprotein and osteocalcin, the early and late
markers of osteogenic differentiation, respectively [39,40].
Materials and methods
Preparation of the hydroxyapatite (HA) scaffolds and synthesis of
dexamethasone-loaded carboxymethylchitosan/poly(amidoamine)
dendrimer (Dex-loaded CMCht/PAMAM dendrimer nanoparticles)
Sintered HA scaffolds with 5 mm diameter and 4 mm height were
obtainedbymeansof impregnating a polyurethane (PU, EurospumaS.A.,
Portugal) sponge with HA powders, as previously reported [34,41,42].
The porosity of the HA scaffolds was evaluated by means of micro-
computed tomography (μ-CT) analysis (Scanco Medicals, Switzerland)
and using the Mimics® image processing software (Materialise,
Belgium). Standardized fabrication conditions enabled the production
of HA scaffolds with a pore size ranging from 50 to 600 μm, and a mean
porosity of 67.8±5.0%. Further details on the HA scaffolds can be found
elsewhere [34].
Carboxymethylchitosan (CMCht) was synthesized by a chemical
modiﬁcation route of chitin (Sigma, Germany) as described by Chen et
al. [43]. Starburst® poly(amidoamine)-carboxylic-terminated dendri-
mers, PAMAM-CT (generation 1.5, 20% (w/v) methanolic solution)
with an ethylenediamine core were purchased from Aldrich (Ger-
many). Dexamethasone-loaded carboxymethylchitosan/poly(ami-
doamine) dendrimer nanoparticles (Dex-loaded CMCht/PAMAM)
were prepared in a stepwise manner as previously described [32]. In
brief, CMCht/PAMAM dendrimer nanoparticles were prepared by
dissolving appropriate amounts of a ﬁrstly synthesized PAMAM-ester
terminated dendrimer and CMCht in a water/methanol solution
(condensation reaction). CMCht/PAMAM dendrimer nanoparticles
with carboxylic-terminated groups were obtained by reductive N-
alkylation. Dexamethasone (Dex, Sigma, Germany) with a ﬁnal
concentration of 5×10−4 M was added to the dendrimer solution.
The precipitation of nanoparticles was carried out by adding a
saturated sodium carbonate (Aldrich, Germany) solution. Then, Dex-
loaded CMCht/PAMAM dendrimer nanoparticles were collected by
ﬁltration, dissolved in ultrapure water and dialyzed using a dialysis
tubing benzoylated (Sigma, Germany) for 2 days. Finally, the
nanoparticles solution was frozen at −80 °C and lyophilized (Tel-
star-Cryodos −80, Spain).
Prior to the in vitro cell culture the HA scaffolds and Dex-loaded
CMCht/PAMAM dendrimer nanoparticles were sterilized under an
ethylene oxide (EtOx) gas atmosphere. No deleterious effect on
physicochemical properties and cytotoxic behaviour of these materi-
als [32,34,35] have been observed after EtOx sterilization.
In vitro cell culture
Isolation and expansion of rat bone marrow stromal cells (RBMSCs)
Seven-week-old Fischer 344/Nmale rats (Japan SLC Inc., Shizuoka,
Japan) were sacriﬁced by administrating an excess of anesthesia, in
accordance to the Ethics Committee at the Tissue Engineering
Research Center (Amagasaki, Japan). Themarrow plugs in the femoral
shafts were ﬂush out using Eagle'sminimum essential medium (MEM,
Nacalai Tesque, Japan) supplemented with 15% fetal bovine serum
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(FBS, JRH Biosciences, USA) and 1% antibiotic–antimycotic (A/B,
Nacalai Tesque, Japan) solution, as described elsewhere [44]. RBMSCs
were transferred to T75 cm2 culture ﬂask and cultured in the presence
of different culture media for the period of 1 week: complete MEM
medium, MEM medium supplemented with 0.01 mg ml−1 Dex-
loaded CMCht/PAMAM dendrimer nanoparticles and MEM medium
supplemented with 10−8 M Dex at 37 °C in a 5% CO2 incubator. The
culture medium was changed within 3 days to remove non-adherent
cells. Then, the culture medium was changed every 2 or 3 days.
Seeding of RBMSCs onto the surface of the HA scaffolds
The RBMSCs (passage 1, P1) were released from substratum with
1 ml of 0.05% trypsin–0.53 mM EDTA (Invitrogen, USA) and centri-
fuged at 900 rpm for 5 min, after culturing for 1 week. The
supernatant was aspirated and the cells re-suspended with 10 ml of
complete culture medium. Cell concentration was determined using
an automatic cell counter (Cell Counter Sysmex F-520, Japan). Prior to
seeding, the viability of the RBMSCs was also analyzed with a
NucleoCounter (ChemoMetec A/S, Denmark) [45]. In addition, the HA
scaffolds were de-aired in MEMmedium under vacuum and following
the protocol described elsewhere [35]. Succinctly, the air was
removed from the porous materials by setting the following
apparatus: ﬁve scaffolds were placed in a 13 ml tube with polystyrene
ventilation cap containing 3 ml of culture medium. A 21 G needle was
attached to a 20 ml syringe and the needle was inserted through the
cap of the tube. By pulling the plunger back completely, a partial
vacuumwas created in the tube. Then, negative pressure was kept for
5–10 min until no bubbling was observed. Finally, one scaffold was
placed in a well of a 96-well TCPS plate and RBMSCs were seeded in a
drop-wise manner, and in static conditions. RBMSCs expanded in a
complete MEM medium, MEM medium supplemented with
0.01 mg ml−1 Dex-loaded CMCht/PAMAM dendrimer nanoparticles
and MEMmedium supplemented with 10−8 M Dex were seeded onto
each HA scaffold. The effect of cell density was evaluated by seeding
different cell numbers (1×106 and 2×105) onto the HA scaffolds.
Finally, RBMSCs/HA scaffold constructs were cultured in the complete
MEM medium for the period of 12 h to allow cell adhesion, under
standard culture conditions.
In vivo study
Subcutaneous implantation
Seven-week-old male Fischer 344 rat (Syngeneic F344/N rat),
same as donor sub-strain and age, were anesthetized by intraperito-
neal injection of pentobarbital (Nembutal, Dainippon Pharmaceutical
Co. Ltd., Japan) at a ﬁnal concentration of 3.5 mg per 100 g of body
weight. The hair of the rat was cut at the implantation area, followed
by washing with tap water and scrubbed with tincture of iodine and
70% ethanol. In each rat, three or four skin incisions (each 1 cm
length) on the dorsal midline below the ear were made. Each
RBMSCs/HA construct was implanted subcutaneously (1.5 to 2 cm
away from the midline at both right and left sides) into the respective
pocket and skin sutured. As a negative control, we used HA implants
without RBMSCs. A maximum of 8 RBMSCs/HA constructs were
implanted per F344/N rat and no prophylactic medication was
administered post-surgery.
After 2 and 4 weeks of implantation, the animals were sacriﬁced
with an overdose of anesthetic and the implants were retrieved. The
in vivo implantation timewas chosen based on our preliminary animal
testing and on previous work reported by Ohgushi group [44,45]. All
Fig. 1. Schematic representation of the experimental strategy (top) and photo of the RBMSCs/HA explants with RBMSCs expanded in MEM medium supplemented with 0.01 mgml−1
Dex-loaded CMCht/PAMAM dendrimer nanoparticles, after 4 weeks of subcutaneous implantation (bottom).
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in vivo experiments were carried out 3 times and using a minimum of
three implants per condition.
Micro-computed tomography (micro-CT) analyses
New bone formation in the retrieved implants was investigated by
micro-computed tomography (micro-CT: MCT-CB 100MF(Z); Hitachi
Medical Corp., Tokyo, Japan) analyses. After 2 and 4 weeks of
implantation, implants were retrieved, rinsed with PBS, and ﬁxed
with 10% formalin at room temperature, overnight. Constructs were
placed on a ﬂat surface for analysis under the micro-CT. X-ray scans
were acquired with a resolution mode of 10 µm (x/y/z) at 50 kV and
150 μA. The analytical conditions were: precision mode, and 7 times
magniﬁcation with an image intensiﬁer ﬁeld of 4.57 cm [46]. Three
explants per condition were analyzed using the 3D Bone Morphom-
etry (TRI/3D-Bon, RATOC System Engineering Co. Ltd., Tokyo, Japan)
software for evaluate the 2D distribution of newly formed bonewithin
the pores of the explants.
The 3D bone formation within the HA implants was quantiﬁed
using the Mimics® image processing software (Materialise, Belgium).
The bone volume (mm3) formed within the explants was quantiﬁed
by setting the following conditions: contrast (1001–4080) and a
threshold (1728–2287). A total of 256 slices per each explant were
analyzed. The threshold used to quantify the new bone formed was
within the range of the predeﬁned threshold set for compact bone in
adult (1686–3012).
Histological evaluation of the explants
After micro-CT analyses, explants were decalciﬁed with K-CX
solution (Falma Co., Tokyo, Japan) for histological analysis. Firstly, the
constructs were dehydrated in an ascending series grade ethanol/
water solution (from 90 to 100%) using an automatic machine for 19 h
followed by washing three times with xylene. Then, specimens were
immersed in parafﬁn at 62 °C and allowed to solidify at−5 °C. Slides
were prepared by cutting the specimens into sections 5 μm thick using
a microtome, and mounted in a micro-slide glass (Matsunami glass
Ind. Ltd., Japan). Parafﬁn was melted by placing the slides in the oven
at 71 °C for 20 min and allowed to cool down at a room temperature.
The remnant parafﬁnwas then eliminated off in hexane for 5 min (S.T.
Chemical, Japan), followed by dipping into an ethylene/propylene
mixture (Clear Plus, Falma Co., Tokyo, Japan) for 3 min. Then, slides
were immersed three times in 100% ethanol for 2 min each time of
immersion. A total of 3 explants per condition were prepared for
histology.
For the Haematoxylin and Eosin (H&E) staining, slides were
sequentially transferred to a 90% ethanol and then to a 70% ethanol
solution and washed with tap water. It followed the staining step,
which consisted of the immersion of the slides into the GM's
Haematoxylin dye (Muto Pure Chemicals Co. Ltd, Tokyo, Japan, GM
Haematoxylin Staining for H&E staining no. 3008-1) for 10 min. It
followed the washing step with tap water for 5 to 10 min. Then, slides
were rinsed with de-ionized water and immersed in a 70% ethanol
solution. Finally, slides were immersed in Eosin dye (Muto Pure
Chemicals Co. Ltd, Tokyo, Japan no. 3204-2) solution for 2 min and
dehydrated in a series of ethanol grades (70%, 90%, and 100%). At last
they were immersed three times in an ethylene/propylene mixture
and then mounted to avoid the formation of bubbles for observation.
For Toluidine blue staining, parafﬁn was melted and slides were
rinsed with ultrapure water. The ground sections were stained with
0.05% Toluidine blue (Muto Pure Chemicals Co. Ltd., Tokyo, Japan) for
30 min. Finally, the slides were dehydrated in a series of ethanol
grades (70%, 90%, and 100%) and mounted for further observation. All
slides were examined under a light microscope (Olympus DP70,
Olympus Co. Ltd, Japan). 2D histological sections are given for the
same bone specimens used in the micro-CT analyses.
Histomorphometry
Bone histomorphometry was carried out using the public domain
image processing program IMAGE J (National Institutes of Health,
Bethesda, MD). The light microscopy photographs of the 2D
histological decalciﬁed sections of each sample were converted to
gray-value images and several ﬁlter steps were performed [47].
Shrinkage percentage observed in decalciﬁed sections [46] was not
considered in the calculations. New bone formation (NB) was
expressed as a percentage of bone volume density (BV/TSV, bone
volume/tissue plus scaffold volume)±standard deviation. A mini-
mum of 12 sections per explant were analyzed.
Quantiﬁcation of alkaline phosphatase (ALP)
Alkaline phosphatase was measured to evaluate osteoblast
differentiation. Prior to the assay, the explants were washed with Ca
and Mg-free PBS solution. Then, explants were transferred to a 2 ml
Eppendorf and pulverized with zirconia's balls as previously reported
[35]. Prior to analysis the samples were sonicated and centrifuged at
12,000 rpm for 1 min at 4 °C. A minimum of 3 explants per condition
were used and experiments were carried out 3 times. To eachwell of a
96-well plate was added an aliquot of supernatant and p-nytrophenyl
phosphate substrate (ZYMED® Laboratories, Invitrogen, USA). The
plate was then incubated in the dark for 30 min at 37 °C and after that
time the reaction was stopped with 1 M NaOH (Panreac, Japan).
Standards were prepared with p-nytrophenol, pNP. Triplicates were
made for each sample and standard. Absorbance was read at 405 nm
(Wallac ARVOsx 1420, Perkin-Elmer Life and Analytical Sciences,
USA), and sample concentrations were read off from the standard
graph. Enzyme activity was expressed either as nmol of pNP released/
explant/30 min.
Quantiﬁcation of osteocalcin
The remnant of each sample used for the ALP assay was treated
with a 20% formic acid solution and stored at 4 °C for 2–3 days.
Afterwards samples were centrifuged at 15,000 rpm for 10 min at
4 °C. Then, the supernatant was passed through a Sephadex™ G-25
column (GE healthcare, Sweden), subsequently concentrated for
performing the enzyme-linked immunosorbent assay (ELISA). A Rat
Osteocalcin EIA kit (no. BT-460, Biomedical Technologies Inc., MA,
USA) was used following the instructions provided by the supplier.
Data was read off from the standard curve obtained with human
osteocalcin and expressed as ng of deposited osteocalcin per explant.
Statistical analysis
One-way analysis of variance (Tukey's multiple comparison test)
was carried out to assess the statistical differences between different
groups. GraphPad Prism software (GraphPad Software Inc., La Jolla,
CA, USA) was used. Statistical signiﬁcance was deﬁned at pb0.05 for a
95% conﬁdence interval.
Results and discussion
Recently, our group [32] has proposed the combinatorial strategy
of tissue engineering principles with nanocarriers towards the
intracellular release and regimented supply of Dex aimed at
controlling the stem cell osteogenic differentiation in the absence of
typical osteogenic cocktails. In the current work, we have investigated
the Dex-loaded CMCht/PAMAM dendrimer nanoparticle bone-form-
ing ability, in vivo. We therefore exposed RBMSCs to 0.01 mg ml−1
Dex-loaded CMCht/PAMAM dendrimer nanoparticles for 1 week,
seeded RBMSCs onto the surface of the HA scaffolds and implanted
the constructs subcutaneously on the back of F344/N rats (Fig. 1, top).
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The concentration of nanoparticles was chosen considering our
previous in vitro Dex release proﬁle [32]. These have shown that
cultures supplemented with 0.01 mg ml−1 Dex-loaded CMCht/
PAMAM dendrimer nanoparticles are exposed to ∼10×10−9 M Dex,
which is in the same magnitude of concentrations to that typically
used in osteogenic cocktails for culturing RBMSCs. Moreover, we have
shown that these either Dex-loaded or non loaded nanoparticles are
internalized by RBMSCs. In another study [35], we demonstrated that
osteogenic differentiation occurs in RBMSCs seeded onto the HA
scaffolds (3D system) in the presence of 0.01 mg ml−1 Dex-loaded
CMCht/PAMAM dendrimer nanoparticles, in vitro. In this study, the
effect of cell number on the bone-forming capacity was also
investigated, since it has been shown that it inﬂuences ectopic bone
formation [37]. Moreover, Ohgushi et al. [46] reported that fresh
RBMSCs cultured in the presence of Dex and seeded onto the HA
scaffolds can show a high level of in vivo bone-forming ability.
Thus, RBMSCs/HA constructs, whose freshly isolated RBMSCs were
pre-cultured in a MEM medium and MEM medium supplemented
with 10−8 M Dex were used as controls.
Fig. 1 (bottom) shows a photograph of the RBMSCs/HA
construct in the back of the F344/N rats, whose RBMSCs were
pre-incubated with 0.01 mg ml−1 Dex-loaded CMCht/PAMAM
dendrimer nanoparticles, after 4 weeks of subcutaneous implanta-
tion. No signs of infection or acute inﬂammatory reaction were
detected at the implantation sites, for all implants. Moreover, we
also preliminary assessed by histology, new bone formation on the
RBMSCs/HA constructs, after 2 weeks of subcutaneous implanta-
tion. At 2 weeks post-implantation no bone formation was detected
in the RBMSCs/HA constructs with RBMSCs expanded in the
complete MEM medium, MEM medium supplemented with
0.01 mg ml−1 Dex-loaded CMCht/PAMAM dendrimer nanoparti-
cles and MEM medium supplemented with 10−8 M Dex and HA
scaffolds without cells (data not shown).
Fig. 2 shows the 2D µ-CT axial images and respective microradio-
graphs of the RBMSCs/HA constructs after 4 weeks of subcutaneous
implantation. The images correspond to the middle section of the HA
explants. It is possible to observe different attenuation areas, having
high (white), medium (light gray), and low (dark gray) intensities.
Thus, we deﬁned the white, light gray, and dark gray areas as HA
scaffold, de novo bone (NB, gray arrows), and ﬁbrovascular tissue with
fat cells, respectively. Massive areas of NB (gray areas) were detected
in all RBMSCs/HA scaffold constructs seeded with 1×106 RBMSCs
(Figs. 2E, I andM) as compared to those of HA constructs without cells
(Fig. 2A) and RBMSCs/HA constructs seeded with 2×105 RBMSCs
(Fig. 2C) pre-cultured in MEM medium.
Fig. 3 reveals the 2Dmicro-CT axial images of themiddle part of HA
explants, after applying the threshold 1728–2287, and that is within
the range of the predeﬁned threshold set for compact bone in adult
(1686–3012). From the ﬁgure it is possible to observe the area
corresponding to NB (green) formation. We were also able to obtain
the 3D architectural data for the NB formed within the explants using
the deﬁned threshold (Table 1). No bone formation was observed for
the HA explants alone (Fig. 3A). By its turn, it was observed that few
green areas attributed to NB within the RBMSCs/HA constructs
seeded with 2×105 RBMSCs expanded in MEMmedium (Fig. 3B). The
NB areas in the RBMSCs/HA constructs seeded with 2×105 RBMSCs
expanded in MEMmedium were restricted to the outer surface of the
explants, i.e. bone ingrowths in the middle part and core of the HA
explants was not observed. Under the micro-CT analysis and using the
predeﬁned threshold (within that for compact bone in adult), the
volume of NB is about 0. On the contrary, NB formation and ingrowths
(osteoconduction) was observed within all sections (top, middle and
bottom) of the HA explants seeded with 2×105 RBMSCs pre-cultured
with Dex and 0.01 mg ml−1 Dex-loaded CMCht/PAMAM dendrimer
nanoparticles (Figs. 3D and F). NB formation and ingrowths (green
areas) were also seen in all sections of the RBMSCs/HA scaffold
constructs seeded with 1×106 RBMSCs (Figs. 3C, E, G). In order to
provide further details on NB formation and distribution within the
HA explants, a movie for each experimental condition is provided (see
Supplementary data).
Fig. 4 shows the light microscopy photographs of the different
RBMSCs/HA explant decalciﬁed sections after 4 weeks of subcutane-
ous implantation, which were stained with Haematoxylin and Eosin
(H&E). The histological ﬁndings showed extensive de novo bone
formation inside the HA pores with cuboid osteoblasts lining (black
arrows) the forming bone matrix in all HA scaffolds seeded with
1×106 RBMSCs (Figs. 4E, F, I, J, M, N), indicating an active bone
formation site. In fact, it is also possible to observe the lacunar spaces
and reminiscent osteocyte-like cells entrapped in the bone matrix
(see Figs. 4H, J and L). Thus, osteocytic lacunae in the lamellar bone are
uniform and regularly distributed with osteoblasts forming a
continuous layer of bone in a unidirectional way typical of mature
bone (NB). In addition, we also detect new bone formation in the HA
scaffolds seeded with 2×105 RBMSCs that were previously expanded
in the presence of 10−8 M Dex (Figs. 4G–H) and 0.01 mg ml−1 Dex-
loaded CMCht/PAMAM dendrimer nanoparticles (Figs. 4K–L). This
data thus conﬁrm that themicro-CT observations in Figs. 2 and 3 (gray
and green areas, respectively) are in fact newly formed bone. From
Figs. 4A–B it can be seen that ﬁbrovascular tissue (F) with fat cells was
formed and that there is no evidence of de novo bone formationwithin
the HA scaffolds. No bone formation was observed for the HA explants
seeded with 2×105 RBMSCs expanded in MEMmedium (Figs. 4C–D),
thus once corroborating the micro-CT ﬁndings. Standardized fabrica-
tion conditions enabled the production of HA scaffolds with a pore
size ranging from 50 to 600 μm, and a mean porosity of 67.8±5.0%.
Thus, the present data shows the importance of the porous size and
interpore connectivity on the cells in-growth since ﬁbrovascular
tissue can be seen in the core of the scaffolds. On the other hand, we
can also observe that bone formationwithin the implants seeded with
1×106 RBMSCs pre-cultured in the presence of 10−8 MDex for 7 days,
is restricted to the outer part of the HA scaffolds (Fig. 4I). In these
explants, extensive formation of adipocytes (A) in an inner part of the
pores of the implants can be seen. This result is not surprisingly since
Porter et al. [27] have shown that the sustained exposure of bone
marrow stromal cells to Dex induces the maturation of an adipocyte
subpopulation within BMSCs, in vitro. In fact, they state that these side
effects can be reduced if Dex is supplied in a regimented manner. This
hypothesis is supported by our histological ﬁndings, since we can
detect that the pores of the RBMSCs/HA constructs are completely
ﬁlled with calciﬁed bone like-matrix (Fig. 4M) and the presence of
adipocytes is decreased, when RBMSCs are pre-cultured with
0.01 mg ml−1 Dex-loaded CMCht/PAMAM dendrimer nanoparticles.
Thus, this data supports the idea that the ex vivo culturing of RBMSCs
with Dex-loaded CMCht/PAMAM dendrimer nanoparticles may be
an effective strategy to, on one hand avoid the RBMSCs adipogenic
differentiation observed in the inner part of the pores upon
withdrawal of dexamethasone and, on the other, direct RBMSCs
towards osteogenic differentiation.
Several authors [8,10,48,49] have been considering that degrada-
tion rate, pore geometry and degree of interconnectivity are
important features to successfully induce de novo bone formation,
since they control the diffusion of oxygen, nutrients and metabolites
to and from the cells. Therefore, the developed HA scaffolds should
own an adequate architecture, since extensive new bone formation
within the macropores was observed. From 2D micro-CT images and
histological observations, new bone connected at the interpore
regions (Figs. 2–4) can be also observed. This is an important
observation as it has been shown that the interpore connections
below 3 µm do not allow cell migration and vascularisation [50]. In
this study, we were able to observe bone formation in the core of the
HA scaffolds, which is an indication that HA scaffolds are osteocon-
ductive and have an adequate interpore size and connection.
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Fig. 5A shows a representative light microscopy photograph of a
decalciﬁed section (H&E staining) of HA scaffolds seeded with 1×106
RBMSCs which were expanded in MEM medium supplemented with
0.01 mg ml−1 Dex-loaded CMCht/PAMAM dendrimer nanoparticles,
after 4 weeks of subcutaneous implantation. Figs. 5B–D show the
respective imaging processing that was carried out to perform the
histomorphometrical analyses. The 2D histological section images
were converted to gray-value images and several ﬁlter steps were
performed [47]. Shrinkage percentage observed in decalciﬁed sections
was not considered in the calculations of the percentage of bone
volume density (BV/TSV). Therefore some care should be taken when
comparing this data with the 3D architectural data obtained using
micro-CT.
Table 1 shows the percentage of BV/TSV in the different implants
determined from the histomorphometrical analyses of the 2D histolog-
ical sections and 3D bone volume obtained using the micro-CT. The
histomorphometrical results using a threshold have shown thatnobone
formation was observed in the HA scaffolds without RBMSCs and HA
seeded with 2×105 RBMSCs expanded in MEMmedium. Bone volume
density in HA seeded with 1×106 RBMSCs expanded in MEM medium
Fig. 2. 2D micro-CT axial images of the explants (middle sections) and respective X-ray photographs, after 4 weeks of subcutaneous implantation: HA scaffolds (A–B), HA seeded
with 2×105 RBMSCs which were expanded in MEMmedium (C–D), HA seeded with 1×106 RBMSCs which were expanded in MEMmedium (E–F), HA seeded with 2×105 RBMSCs
which were expanded in MEMmedium supplemented with 10−8 M dexamethasone (G–H), HA seeded with 1×106 RBMSCs which were expanded in MEMmedium supplemented
with 10−8 M dexamethasone (I–J), HA seeded with 2×105 RBMSCs which were expanded in MEM medium supplemented with 0.01 mg ml−1 Dex-loaded CMCht/PAMAM
dendrimer nanoparticles (K–L), and HA seeded with 1×106 RBMSCs which were expanded in MEM medium supplemented with 0.01 mg ml−1 Dex-loaded CMCht/PAMAM
dendrimer nanoparticles (M–N). We deﬁned the white, light gray, and dark gray areas as HA scaffold, new bone formation (black arrows), and ﬁbrovascular tissue with fat cells,
respectively.
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was 27.1±7.1%. By its turn, HA seededwith 2×105 and 1×106 RBMSCs
expanded in MEMmedium supplemented with 10−8 M Dex was 6.9±
4.7% and 36.4±9.2%, respectively. Finally, HA seeded with 2×105 and
1×106 RBMSCs expanded in MEM medium supplemented with
0.01 mgml−1 Dex-loaded CMCht/PAMAM dendrimer nanoparticles
was 30.5±6.0% and 38.1±5.7%, respectively. These results have
Fig. 3. 2Dmicro-CT axial images of the explants (middle sections) to which was applied a threshold of 1728–2287, after 4 weeks of subcutaneous implantation: HA scaffolds (A), HA
seeded with 2×105 RBMSCs which were expanded in MEM medium (B), HA seeded with 1×106 RBMSCs which were expanded in MEM medium (C), HA seeded with 2×105
RBMSCs which were expanded in MEM medium supplemented with 10−8 M dexamethasone (D), HA seeded with 1×106 RBMSCs which were expanded in MEM medium
supplemented with 10−8 M dexamethasone (E), HA seeded with 2×105 RBMSCs which were expanded in MEM medium supplemented with 0.01 mg ml−1 Dex-loaded CMCht/
PAMAM dendrimer nanoparticles (F), and HA seeded with 1×106 RBMSCs which were expanded in MEM medium supplemented with 0.01 mg ml−1 Dex-loaded CMCht/PAMAM
dendrimer nanoparticles (G).
Table 1
Percentage of bone volume density (BV/TSV) calculated from the histomorphometrical analyses of the 2D histological sections of the different explants, after 4 weeks of
subcutaneous implantation. A minimum of 12 sections per explant were analyzed. The bone volume (3D analysis) formed within the explants was also quantiﬁed using micro-CT
technique using a contrast between 1001 and 4080 and a threshold of 1728–2287. The threshold used to quantify the new bone formed was within the range of the micro-CT
thresholding for compact bone in adult (1686–3012). A movie for each explant is provided as Supplementary data.
p value: ***b0.001; **b0.01; and *b0.05.
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demonstrated that there is a signiﬁcant increase (pb0.01) in NB within
HA seeded with 1×106 RBMSCs pre-cultured with 0.01 mgml−1 Dex-
loaded CMCht/PAMAM dendrimer nanoparticles as compared to HA
seeded with 2×105 RBMSCs pre-cultured with 0.01 mgml−1 Dex-
loaded CMCht/PAMAM dendrimer nanoparticles. A signiﬁcant increase
(pb0.001) in NB within HA seeded with 2×105 RBMSCs pre-cultured
with 0.01 mgml−1 Dex-loaded CMCht/PAMAM dendrimer nanoparti-
cles can also be seen as compared to both HA explants seeded with
2×105 RBMSCs pre-culturedwith Dex and seededwith 2×105 RBMSCs
pre-cultured in MEM. These results revealed that cell number and
culture conditions are critical factors in promoting de novo bone
formation, in vivo. These results are corroborated by thenon-destructive
micro-CT analyses (bone volume), which have shown that no bone
formation was observed in the HA explants without RBMSCs and HA
explants seeded with 2×105 RBMSCs pre-cultured in MEMmedium.
The present data revealed that porous HA ceramics alone do not
induce bone formation upon subcutaneous implantation in the back of
the F344/N rats. However, bone formation could be detected by
seeding RBMSCs onto the HA scaffolds, when the cell number used
was 1×106 cells. Moreover, our ﬁndings corroborates previous ones
[22–24], as it demonstrated once the need of cells to be exposed to
Dex for promoting de novo bone formation. Despite, in this work we
have shown that Dex-loaded CMCht/PAMAM dendrimer nanoparti-
cles induced a superior new bone formation as compared to that of
RBMSCs expanded in MEM medium supplemented with 10−8 M Dex,
the typical concentration used in osteogenic media [44]. This was
particularly evident and statistically signiﬁcant when seeding 2×105
RBMSCs onto the surface of the HA scaffolds. Our present data is
relevant if we consider that, to our knowledge, no reports have shown
pores of implanted ceramics completely ﬁlled with newly formed
bone when seeded with low cell numbers, after 4 weeks of
implantation. For example, Nishikawa et al. [10] observed that bone
formation in the RBMSCs/HA scaffolds after 2 weeks of ectopic
implantation occurred, but constructs were previously cultured in
vitro in an osteogenic medium. By its turn, Arinzeh et al. [8] observed
low amounts of new bone formation in the HA scaffolds seeded with
5×106 cells, and mainly restricted to peripheral pores, after 6 weeks.
It has been reported [27,51,52] that sustained exposure of bone
marrow stromal cells to Dex down-regulate collagen type I produc-
tion in vitro, both in humans and animalmodels. To further investigate
Fig. 4. Light microscopy photographs of the explants sections stained with Haematoxylin and Eosin (decalciﬁed sections), after 4 weeks of subcutaneous implantation: HA scaffolds
(A–B), HA seeded with 2×105 RBMSCs which were expanded inMEMmedium (C–D), HA seeded with 1×106 RBMSCs which were expanded inMEMmedium (E–F), HA seeded with
2×105 RBMSCs which were expanded in MEMmedium supplemented with 10−8 M dexamethasone (G–H), HA seeded with 1×106 RBMSCs which were expanded inMEMmedium
supplemented with 10−8 M dexamethasone (I–J), HA seeded with 2×105 RBMSCs which were expanded in MEM medium supplemented with 0.01 mg ml−1 Dex-loaded CMCht/
PAMAM dendrimer nanoparticles (K–L), and HA seeded with 1×106 RBMSCs which were expanded inMEMmedium supplemented with 0.01 mg ml−1 Dex-loaded CMCht/PAMAM
dendrimer nanoparticles (M–N). It is possible to observe representative areas of de novo bone formation (NB), ﬁbrous tissue (F) and adipocytes (A). White arrows indicate the
interconnected pores. Black arrows show the cell lining which is suggestive of active osteoblasts. Osteocytes can also be visualized (*).
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proteoglycan extracellular matrix synthesis (ECM) [37], we stained
the explant sections with the methacromatic Toluidine blue (Fig. 6).
Methacromasia was weakly observed in implants where new bone
formation was formed (Figs. 6E–F, G–H, I–J, and K–L). The other
explants had no such ﬁndings (Figs. 6A–B, and C–D). However,
enhanced methacromasia was evident within HA explants seeded
with RBMSCs pre-cultured in the presence of 0.01 mg ml−1 Dex-
loaded CMCht/PAMAM dendrimer nanoparticles (Figs. 6M–N), which
shows the ECM rich of proteoglycans. This data suggests that
supplying Dex in a regimented manner can enhance proteoglycan
extracellular matrix synthesis. No cartilaginous like-matrix [53] was
observed.
Osteoblast differentiation is accompanied by the differential and
temporal expression of several osteoblastic markers such as ALP,
osteopontin, collagen type I, and osteocalcin [39]. In order to
demonstrate the osteogenic capacity of the different explants
quantitatively, we measured the ALP activity and osteocalcin
contents, after 4 weeks of implantation. Fig. 7 shows the ALP activity
and osteocalcin content of the HA scaffolds without RBMSCs and the
several RBMSCs/HA construct explants. As seen for bone formation,
the ALP activity is signiﬁcantly higher (pb0.001) in all the HA explants
seeded with 1×106 RBMSCs as compared to that seeded with 2×105
RBMSCs (Fig. 7a). This data thus suggests that osteogenic differenti-
ation did occur in cultures with and without Dex, which corroborates
previous histological ﬁndings. It can be seen that ALP is signiﬁcantly
higher (pb0.001) when RBMSCs were expanded in a culture medium
with 0.01 mg ml−1 Dex-loaded CMCht/PAMAM dendrimer nanopar-
ticles and 10−8 M Dex as compared to explants whose RBMSCs were
expanded inMEMmedium. In addition, no signiﬁcant differenceswere
observed among the explants seededwith 1×106 RBMSCswhose cells
were expanded in a culturemediumwith Dex-loaded CMCht/PAMAM
dendrimer nanoparticles and 10−8 M Dex. Signiﬁcant differences in
ALP activity were observed among the explants seeded with 2×105
RBMSCs. It can be seen that ALP activity in the explants where RBMSCs
were expanded in a culture medium with 0.01 mg ml−1 Dex-loaded
CMCht/PAMAM dendrimer nanoparticles presented signiﬁcantly
higher (pb0.05) ALP levels as compared to that of culture medium
whose RBMSCs were both pre-cultured with 10−8 M Dex and MEM,
which is consistent with the higher bone formation observed. In other
words, our data are in full agreementwith previousﬁndings [26,54], as
we found that a continuous treatment with Dex consistently increases
the ALP activity, which is an indication of the osteogenic commitment
of RBMSCs. Thus, it can be seen that Dex induced the early osteoblastic
differentiation and potentiate new bone formation. Moreover, HA
scaffolds without RBMSCs and RBMSC/HA constructs seeded with
2×105 RBMSCs expanded in MEM medium showed decreased ALP
activity, which once corroborates our ﬁndings on the important role of
both Dex supply and cell number in promoting de novo bone
formation.
Fig. 7b shows osteocalcin content of the RBMSCs/HA constructs
explants, after 4 weeks of subcutaneous implantation. Osteocalcin
content is signiﬁcantly higher when RBMSCs were expanded in
culture medium with 0.01 mg ml−1 Dex-loaded CMCht/PAMAM
dendrimer nanoparticles as compared to HA explants where RBMSCs
were cultured in MEM medium. The increase in osteocalcin
expression indicates an advancing differentiation. Similarly to what
was observed for ALP activity, osteocalcin content in the HA explants
without cells is signiﬁcantly decreased as compared to all HA explants
with seeded RBMSCs. In addition, it is possible to observe that
osteocalcin content did not vary signiﬁcantly in the explants seeded
with different cell numbers but pre-cultured in identical culture
conditions (B–C). Moreover, no signiﬁcant difference in osteocalcin
content was found in HA explants with RBMSCs exposed to Dex as
compared to HA explants seeded with RBMSCs pre-cultured with
0.01 mg ml−1 Dex-loaded CMCht/PAMAM dendrimer nanoparticles.
These results can be explained by the unresponsiveness of osteocalcin
to long-term exposure to Dex in our experimental study as this late
osteoblastic marker appears to reach amaximum just before or during
mineralized tissue formation [55]. In addition, it has been shown
[56,57] that the expression of osteocalcin increases with mineral
deposition, while ALP levels decreases. Another possible explanation
for our ﬁndings has been advanced by Porter et al. [27], which
demonstrated that Dex induces the expression of bone sialoprotein,
but not osteocalcin. Thus, osteocalcin expression may be stimulated
Fig. 5. Light microscopy photographs of an explant section corresponding to the HA seeded with 1×106 RBMSCs which were expanded in MEM medium supplemented with
0.01 mg ml−1 Dex-loaded CMCht/PAMAM dendrimer nanoparticles, after 4 weeks of subcutaneous implantation: decalciﬁed section stained with Haematoxylin and Eosin (A), and
respective imaging processing (B–D). It is possible to observe representative areas of de novo bone formation (NB), HA scaffolds (HA) and ﬁbrous tissue (F).
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through a different pathway. Despite, these results conﬁrmed the
osteogenic capacity of the HA scaffolds seeded with 1×106 RBMSCs
and supported the fact that exposure of Dex prior and during
implantation time can result in a superior de novo bone formation.
Moreover, this study supported previous ones [32,35], and showed
that CMCht/PAMAM dendrimer nanoparticles can supply Dex to
RBMSCs, thus acting at both early and late stages to direct proliferative
osteoprogenitor cells toward terminal maturation. The superior role
of Dex-loaded CMCht/PAMAM dendrimer nanoparticles towards
enhancing ALP levels was particularly evident when seeding 2×105
RBMSCs per HA scaffold. Despite the interesting data, we envision
performing in vivo studies for longer implantation periods to clarify
further, the effect of the regimented supply of Dex delivered via Dex-
loaded CMCht/PAMAM dendrimer nanoparticles versus withdrawal
of Dex on the osteogenic differentiation and bone-forming ability of
the RBMSCs.
In conclusion, this work demonstrated that cell number and ex vivo
culturing strategies greatly inﬂuence the osteogenesis and de novo
bone formation, in vivo. RBMSCs expanded with 0.01 mg ml−1
dexamethasone-loaded carboxymethylchitosan/poly(amidoamine)
dendrimer nanoparticles and seeded at low cell number on the
surface of the HA scaffolds enhanced the ectopic bone formation, after
4 weeks of subcutaneous implantation in the back of Fischer 344 rats.
This study reveals that the novel dexamethasone-loaded carboxy-
methylchitosan/poly(amidoamine) dendrimer nanoparticles may be
beneﬁcial as intracellular nanocarrier and supply of Dex aimed at
modulate and direct stem cell differentiation towards osteogenic
phenotype, enhance proteoglycan extracellular matrix synthesis and
superior ectopic de novo bone formation. Moreover, the architecture
of HA scaffolds proved to be an adequate support for osteogenic
differentiation of bone marrow derived osteoblast and bone forma-
tion, in vivo. Thus, in this work it has been demonstrated that the
innovative tissue engineering strategy proposed is effective on
promoting de novo bone formation in vivo and avoid the need of
culturing stromal cells in the presence of typical osteogenic cocktails,
prior to implantation.
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